Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 4/20 | 0.37 |
| ▸ | JAK1 | P23458 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26341561 | 0.91 | ALDH1A1 (0.45) | ALDH1A1LMNAMAPTGPR119DDB1 | |
| SCHEMBL16985361 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTGPR119DDB1 | |
| SCHEMBL29107817 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTGPR119DDB1 | |
| SCHEMBL30955736 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTGPR119DDB1 | |
| SCHEMBL16985425 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTGPR119DDB1 | |
| SCHEMBL16794076 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTGPR119DDB1 | |
| SCHEMBL30955772 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNAMAPTGPR119DDB1 | |
| SCHEMBL15192197 | 0.86 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTGPR119DDB1 | |
| SCHEMBL18383140 | 0.86 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTGPR119DDB1 | |
| SCHEMBL16794183 | 0.86 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTGPR119DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025017116-A1 | PHARMACEUTICAL COMPOUNDS HAVING ACTIVITY AS WEE1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20180354956-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-13 | — | — | US | disclosed |
| US-10087186-B2 | Compounds as LRRK2 kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-02 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | ALDH1A1 4033/4885LMNA 1157/4885MAPT 9/4885 |
| US-10087186-B2 | Compounds as LRRK2 kinase inhibitors | LRRK2, PINK1, PARK7 | ALDH1A1 4132/4885LMNA 716/4885MAPT 11/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | ALDH1A1 3795/4885LMNA 802/4885MAPT 6/4885 |
| US-20180354956-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | ALDH1A1 3795/4885LMNA 802/4885MAPT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.